RxDoctor Payments DataLook up a doctor →

Bob Geng, MD

Allergy & Immunology · San Diego, CANPI 1356570758

Payments from drug & device makers

$5,979,907in general payments, 2019–2025

Across 3,659 payments — averaging $1634.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2.1M
  • GSK$641K
  • Regeneron Healthcare Solutions, Inc.$500K
  • Regeneron$308K
  • AstraZeneca$271K
  • Incyte Corporation$245K
  • plus $1.9M from 54 others
$144,751in research payments, 2019–2025

Across 35 payments — averaging $4135.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • LEO Pharma Inc.$70K
  • Lilly USA, LLC$41K
  • Pfizer$22K
  • F. Hoffmann-la Roche AG$6K
  • Amgen$2K
  • Sanofi$2K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$440,03113%
  • Speaking & faculty fees$2,231,18767%
  • Travel & lodging$528,63316%
  • Food & beverage$107,3473%
  • Education$9,2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi502$2,137,283
GSK524$640,642
Regeneron Healthcare Solutions, Inc.533$499,792
Regeneron54$307,648
AstraZeneca62$270,685
Incyte Corporation124$245,095
Takeda Pharmaceuticals U.S.A., Inc.205$226,102
Grifols USA, LLC186$214,225
AbbVie176$187,839
Amgen(2 entities)141$179,316
Pfizer126$111,469
Lilly USA, LLC81$103,326
Eli Lilly43$92,853
Biocryst US Sales Co., LLC94$89,331
Genentech, Inc.16$86,375
Novartis89$61,647
Shire North American Group Inc91$58,954
ADMA Biomanufacturing LLC60$57,695
Pharming Healthcare, Inc.79$43,318
Chiesi USA, Inc.12$42,655
Sanofi-aventis U.S. LLC23$37,729
Optinose US, Inc.51$26,828
Grifols Shared Services North America, Inc.34$26,439
Repro Med Systems Inc3$25,359
LEO Pharma Inc.34$22,398
CSL Behring53$21,260
Insmed, Inc.12$19,804
Octapharma USA, Inc.22$19,274
Ionis Pharmaceuticals, Inc.21$16,489
Leadiant Biosciences, Inc.12$16,362
Astrazeneca UK Limited2$11,156
Arcutis Biotherapeutics, Inc.6$9,932
Teva Pharmaceuticals USA, Inc.20$9,654
Biocare, Inc.1$9,000
GC Biopharma USA, Inc.5$7,323
Alk-abello, Inc29$7,285
Kedrion Biopharma, Inc.8$6,483
Koru Medical Systems, Inc.1$6,232
Sanofi US Services Inc.2$5,400
Biocryst Pharmaceuticals, Inc.4$3,812
Kedrion Biopharma Inc.8$3,531
Genentech USA, Inc.14$2,326
Mitsubishi Tanabe Pharma Development America, Inc.2$1,300
Blueprint Medicines Corporation13$1,092
FFF Enterprises, Inc.1$1,000
Tersera Therapeutics LLC4$925
Bio Products Laboratory USA, Inc.11$774
F. Hoffmann-la Roche AG1$669
Kyowa Kirin, Inc.7$609
Galderma Laboratories, L.p.8$566
Dermavant Sciences, Inc.5$416
Kaleo, Inc.18$354
Advanced Respiratory, Inc2$327
Greer Laboratories, Inc.3$231
ARS Pharmaceuticals Operations, Inc.3$187
Boehringer Ingelheim2$172
Merck1$125
Aimmune Therapeutics, Inc.1$124
E.r. Squibb & Sons, L.L.C.1$118
UCB, Inc.1$116

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,979,907 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$3,952
Medicare patients
15
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab13$47,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,027
Montelukast Sodium13$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$640,642$11,02718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →